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SUMMARY
The implantation of heparin-coated stents was reported to be well tolerated, but there
are conflicting results about acute in-hospital complications, (sub)acute thrombosis rates,
and long-term follow-up compared to uncoated stents. We compared the angiographic and
clinical results after coronary placement of two stent models: the heparin-coated pre-
mounted Jostent and the uncoated premounted NIR stent. Of  710 patients revascularized,
a total of 426 patients received Jostent (n = 230) or NIR stent (n = 196) implantation. The
primary end points were acute or subacute thrombosis, urgent CABG, AMI or death,
while the secondary end points were the comparison of the restenosis rates of the stents
at the 6th month and of the functional angina classification of the stent groups at the 1st,
6th and 12th months. There were no significant differences between the Jostent and NIR
stent groups regarding angiographic and procedural success. Acute thrombosis rates in the
Jostent and NIR stent groups were similar while no subacute thrombosis was observed in
either group. The major adverse cardiac event rates of the groups also did not differ.
Angiographic restenosis occurred in 17% of the Jostent group and 16% of the NIR stent
group (NS). The combined clinical and angiographic restenosis rate was also similar
between the Jo and NIR groups (19% and 18%, respectively). Comparison of functional
angina classes at the 1st, 6th and 12th months revealed no significant difference between the
study groups.
In conclusion, when compared with implantation of an uncoated premounted NIR
stent, implantation of a heparin-coated premounted Jostent does not provide any more
benefit with respect to initial efficacy, sub(acute) thrombosis and 6-month restenosis rates
and 12-month clinical outcomes.  (Jpn Heart J 2003; 44: 889-898)
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In an animal model it has been suggested that stent surface material and geomet-
ric configuration may be more important than operator-dependent variables in
determining the degree of neointimal hyperplasia and thrombosis.1) Data from
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animal studies indicate that heparin-coated stents were shown to be effective in
reducing thrombosis in porcine coronary arteries.2) Heparin coating of metallic
coronary stents decreases their thrombogenicity but does not improve late vessel
patency and neointimal hyperplasia at follow-up in a porcine coronary model.3)
Animal studies using high-activity heparin-coated stents have shown that up to
80% of the antithrombin III binding activity is lost 4 weeks after stent implanta-
tion.2) Nevertheless, reductions in the rates of stent thrombosis in animal studies
led to the evaluation of high-activity end-point-attached heparin-coated stents in
the Benestent II pilot study4) and the Benestent II randomized trial.5) The purpose
of this study was to investigate and compare the acute and subacute thrombosis
and restenosis rates of a heparin-coated Jostent and a conventional NIR stent, a
novel second generation tubular stent that was designed to overcome some of the
limitations of the earlier Palmaz-Schatz (PC) stent design. 
MATERIALS AND METHODS
We performed an analysis of the cardiac catheterization database from Jan-
uary 1998 through May 1999 and found data on all patients who underwent cor-
onary revascularization in which a premounted Jostent or NIR stent was
attempted in all treated segments. Of the 710 patients who were revascularized
during this period, a total of 426 patients received Jostent or NIR stent implanta-
tion. At the beginning of the study, the patients in both groups were evaluated in
terms of clinical and demographic properties. The patients were informed about
the procedure and gave their written informed consent. Coronary angiography
was performed according to conventional techniques through the femoral route.
All of the subjects revascularized had a > 70% diameter stenosis in their native
vessels. Percent diameter stenosis was assessed during diastole using the most
severe stenosis in at least two angiographic views. The proximal and distal refer-
ence vessel diameters were averaged to obtain a mean reference vessel diameter.
The same measurements were used in the same views during follow-up angio-
grams. A 7-Fr. guiding catheter and a 0.014 inch coronary guidewire were used
as the delivery system. During the procedure, a total of   10,000 to 15,000 units of
heparin were given as a bolus injection. Choice of predilatation with balloon
catheters or of stent type was at the discretion of the operator. Stents were sized
according to a stent-to-artery ratio of 1.1 to 1.0. Procedural success was defined
as successful deployment of the stent in the absence of a major cardiac event
[MACE - Death, acute myocardial infarction (AMI), coronary artery bypass
grafting (CABG)]. High-pressure inflations (> 12 atm.) were used to optimize
stent expansion after initial deployment of the stent. A < 10% residual diameter
stenosis following final deployment of the stent was used to define angiographic
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success for stent implantation. Patients were given ticlopidine and aspirin for 1
month and indefinitely, respectively, following successful stent implantation.
Complete blood count was performed on all patients who received ticlopidine at
2 and 4 weeks.
Control coronary angiography was performed in available patients in both
groups following a 6 month follow-up. Repeat percutaneous transluminal coro-
nary angioplasty (PTCA) was attempted in patients with restenosis who accepted
reintervention. Other patients in both groups were assessed by clinical informa-
tion obtained through an interview during outpatient clinic visits or from the
patient or family by telephone.
The primary clinical end points of the study were acute (occurring in the
interventional site while the guiding catheter was still in place or in the first day
following stent implantation) or subacute (occurring after removal of the guiding
catheter following stent implantation or outside the interventional site) thrombo-
sis, urgent CABG, AMI or death, while the secondary end points were the com-
parison of functional angina classes of patients in both groups, according to the
Canadian Cardiovascular Society (CCS) classification, at the 1st, 6th, and 12th
month and of the restenosis rates of the stents at the 6th month. Clinical restenosis
for both stent groups was defined as having symptoms or signs of ischemia at the
6th month follow-up. Angiographic restenosis was defined as a  diameter stenosis
of > 50% at 6-month reangiography measured at any point within the stented seg-
ment.
Continuous variables are expressed as the mean ± SD. Absolute numbers
(%) were used for categorical variables. Statistical analysis was performed using
Student's t-tests for continuous data and chi-square analysis for categorical data.
Statistical significance was assumed at the 5% level.
RESULTS
The baseline clinical characteristics are shown in Table I. There were no sig-
nificant differences in age, sex, diagnosis, risk factors, or other patient character-
istics. Angiographic data for both stent groups are outlined in Table II. Lesion
characteristics in both groups, according to the American College of Cardiology/
American Heart Association Task Force criteria, were identical. The diameter
stenosis before stenting did not differ significantly among the groups. The differ-
ence between the number of diseased vessels in the groups was not significant.
Table III shows the procedural and postprocedural characteristics of the groups.
With respect to indications for revascularization, the differences between the
groups were not significant. Angiographic success and procedural success were
similar in the 2 groups. The number of MACE in the Jo and NIR groups did not
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Table I. Patient Characteristics
Jo Group (n=230) NIR Group (n=196) P Value
Male (%)
Age (years)
Stable angina pectoris (%)
Unstable angina pectoris (%)
Acute myocardial infarction (%)
Recent AMI (%)
Prior AMI (%)
Prior streptokinase (%)
Prior PTCA (%)
Prior CABG (%)
Coronary risk factors (%)
                         Smoking history
                                    Diabetes
           Cholesterol ≥ 200 mg/dL
                             Hypertension
                            Family history
184 (80)
57 ± 10 
81 (35)
83 (36)
37 (16)
60 (26)
30 (13)
0
14 (13)
4 (2)
104 (45)
25 (11)
41 (18)
81 (35)
41 (18)
165 (84)
56 ± 9
43 (22)
94 (48)
24 (12)
43 (22)
35 (18)
2 (1)
10 (5)
4 (2)
76 (39)
27 (14)
38 (20)
65 (33)
31 (16)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Data presented are the mean ± SD or number (%) of patients. AMI= acute myocardial 
infarction; PTCA= percutaneous transluminal coronary angioplasty; CABG= coronary 
artery bypass grafting; NS= nonsignificant.
Table II. Angiographical Data
Jo Group (n=230) NIR Group (n=196) P Value
Number of lesions (%)
                                      L AD
                                         CX
                                       RCA
ACC/AHA lesion type (%)
                                     　   A
                                          B1
                                          B2
                                            C
% diameter stenosis
Reference vessel diameter (%)
                                   < 3 mm
                                   ≥ 3 mm
Number of diseased vessels (%)
                        1 vessel disease
                        2 vessel disease
                        3 vessel disease
254
129 (51)
53 (21)
72 (28)
31 (12)
53 (21)
134 (53)
36 (14)
88 ± 12
177 (70)
77 (30)
119 (52)
86 (37)
25 (11)
224
114 (51)
34 (15)
76 (34)
22 (10)
52 (23)
121 (54)
29 (13)
89 ± 12
134 (60)
90 (40)
82 (42)
84 (43)
30 (15)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Data presented are the mean ± SD or number (%) of patients or lesions. LAD=left 
anterior descending artery; CX=circumflex artery; RCA=right coronary artery; ACC/
AHA=American College of Cardiology / American Heart Association; NS= nonsig-
nificant.
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differ significantly. Subacute thrombosis was not observed in either group. The
difference between the number of stents per patient did not reach statistical sig-
nificance. Bleeding complications requiring blood transfusion or surgical repair
were not encountered in either group. The patients in both groups were dis-
charged home after a mean period of 1.5 days.
The clinical end points at the 6th month are outlined in Table IV. The angio-
graphic restenosis rate did not differ significantly between the Jo and NIR groups.
The combined clinical and angiographic restenosis rate also did not reach statis-
tical significance between the groups. Repeat PTCA of the restenotic segments
was successful without any complications. The differences between the rates of
any event at 6th month follow-up were not significant.  There were no significant
differences between the study groups with respect to the functional angina classes
according to the CCS classification of the patients at the 1st, 6th and 12th month.
The angina classification of the patients in the two groups is summarized in Table
V.
Table III. Procedural and Postprocedural Characteristics
Jo Group (n=230) NIR Group (n=196) P Value
Indication for revascularization (%)
   Planned
   Unplanned
                             Suboptimal result
                                  Acute closure
   Restenosis following prior PTCA
Angiographic success (%)
Major cardiac event (%)
                                              Death
                                               AMI
                                 Urgent CABG
Procedural success (%)
Acute thrombosis (%)
Subacute thrombosis (%)
Number of stents / patient (%)
                                      Single stent
                                           2 stents
                             3 stents and over
Maximum atmosphere
Predilatation (%)
Blood transfusion (%)
Surgical repair (%)
158/254 (62)
58/254 (23)
20/254 (8)
18/254 (7)
100
2 (1)
1
1
0
252/254 (99)
4 (2)
0
205 (89)
21 (9)
4 (2)
12.8 ± 2
221 / 254 (87)
0
0
146/224 (65)
42/224 (19)
25/224 (11)
11/224 (5)
100
7 (4)
4
1
2
217/224 (97)
2 (1)
0
151 (77)
33 (17)
12 (6)
13.0 ± 2
188 / 224 (84)
0
0
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Data presented are the mean ± SD or number (%) of patients or lesions. PTCA= percuta-
neous transluminal coronary angioplasty; AMI= acute myocardial infarction; CABG= 
coronary artery bypass grafting; NS= nonsignificant.
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DISCUSSION
Stents have been shown to successfully treat acute or threatened vessel clo-
sure after failed PTCA6) and to significantly reduce restenosis.7-9) Adjunctive use
of potent antiplatelet agents such as ticlopidine or clopidogrel markedly
decreased the incidence of stent thrombosis and bleeding complications.10) To fur-
ther improve the clinical results of coronary stenting, attention was directed to
coating the stent with material that would reduce their inherent thrombogenicity
and decrease the incidence of in-stent restenosis.2,4,5,11-29) Most coatings tested are
placed mainly to provide a biologically inert barrier between the stent surface and
the circulating blood. In contrast to these, immobilized-heparin surface coatings
have been studied as means of providing a biologically active exterior that inter-
acts with the circulating blood.30) Some of the heparin-coated stents available for
clinical use include the heparin-coated PS stent, on which heparin is end-linked
Table IV. Clinical End Points at 6 Months
Jo Group (n=230) NIR Group (n=196) P Value
Control angiography (%)
Combined clinical and angiographic
restenosis rate (%)
Angiographic restenosis rate (%)
TVR (%)
AMI (%)
CABG (%)
Death (%)
CVA (%)
Any event at 6 month follow-up
100 (43)
44 / 230 (19)
17 / 100 (17)
10 / 100 (10)
2 (1)
2 (1)
5 (2)
0
19 / 230 (8)
68 (35)
36 / 196 (18)
11 / 68 (16)
7 / 68 (10)
2 (1)
4 (2)
8 (4)
0
21 / 196 (11)
NS
NS
NS
NS
NS
NS
NS
NS
NS
Data presented are number (%) of patients; TVR: target vessel revascularization; 
AMI=acute myocardial infarction; CABG=coronary artery bypass grafting; CVA=cere-
brovascular accident; any event=TVR, AMI, CABG, death or CVA; NS=nonsignificant.
Table V. Angina Classification of Patients in Jo Stent and NIR Groups (*)
No angina (%) Class I (%) Class II (%) Class III (%) Class IV (%)
1st month
6th month
12th month
Jo
89
89
86.3
NIR
83.5
86
85.1
Jo
1.8
1.8
2.7
NIR
7.2
4.3
6.4
Jo
9.2
4.6
2.7
NIR
8.2
3.2
2.1
Jo
0
3.7
2.7
NIR
1
3.2
4.3
Jo
0
0.9
5.5
NIR
0
3.2
2.1
(*) Comparison of functional angina classes of patients according to Canadian Cardio-
vascular Society classification revealed no significant difference.
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to the stent surface with a patented Carmeda coating technology, the Wiktor hep-
arin-coated stent (Hepamed coating),29) and the Jostent (Corline heparin coating),
on which heparin is randomly attached.30) The heparin-coated Wiktor stent
appeared to be an efficacious device to treat Benestent-like lesions, yielding
angiographic and clinical results comparable to a heparin-coated PS stent.29) A
stent coated with releasable heparin has been reported to be beneficial in reducing
neointimal formation and subsequent in-stent restenosis in porcine coronary
arteries.31) The implantation of stents coated with polyamine and end-point-
attached heparin in stable patients with one significant de novo coronary lesion is
well tolerated, is associated with no (sub)acute stent thrombosis, and results in a
favorable event-free survival after 6 months. Meanwhile, there was no compel-
ling evidence indicating that heparin coating is actively affecting the neointimal
hyperplasia within the stent.4) Over a 12-month follow-up, a strategy of elective
stenting with the heparin-coated PS stents has been reported to be more effective
but also more costly than balloon angioplasty.32) A randomized study with blind
angioscopic assessment for heparin-coated versus uncoated PS stent in  native
coronary circulation reported that the implantation of heparin-coated stents in a
nonselected population was well tolerated and associated with no clinical or
angioscopic evidence of new thrombus formation, resulting in favorable long-
term clinical and angiographic outcomes.33) Some of the limitations of the earlier
PS stent design led to the development of a novel second generation tubular NIR
stent. The NIR stent showed excellent deliverability with slightly better acute
angiographic results and an equivalent or better 9-month target vessel failure rate
when compared with the PS stent.34) Our study shows that the NIR stent is as
favorable as the heparin-coated Jostent with regard to early and late clinical and
angiographic outcomes. Our findings that both MACE and acute thrombosis rates
were similar in the heparin-coated Jostent and the NIR stent groups could be
explained by the state that procedural failure is mainly due to dissection or inad-
equate expansion of the stent and is independent from the stent structure or stent
coating. Absence of subacute thrombosis and major bleeding complications in
both the Jo and NIR groups in our study is in accordance with the findings that
careful and intensive monitorization of heparin administration during the proce-
dures until the removal of femoral sheaths and that use of the potent antiplatelet
agent ticlopidine for 1 month have been shown to prevent subacute thrombosis
rates and bleeding complications due to anticoagulant medication.
It has been reported that controversy exists about the usefulness of heparin
coating.35) Although the incidence of subacute stent thrombosis was extremely
low in the Benestent II trial (0.2% compared with 3.5% in Benestent I using a
noncoated stent), the trials may not be comparable concerning this particular
complication because the Benestent I trial was conducted in an era of different
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stenting protocols. Otherwise, angiographic restenosis rates were similar (22%
and 18% for Benestent I and II studies, respectively)36,37) When compared with
the uncoated Jostent, the Corline heparin coating of the Jostent had no impact on
the in-hospital complication rate, stent thrombosis, or restenosis.38) The similar
effects for heparin coated Jostent and NIR stent implantation on restenosis rates
and CCS angina classification in our study support the knowledge that, in addi-
tion to thrombus formation at the site of intervention, smooth muscle cell prolif-
eration, arterial remodeling, and vascular recoil are also responsible for the
development of restenosis39); however, the relative importance of each remains to
be determined. Although the same data confirm the influence of the coronary
stent design, especially of the strut thickness of the stents, on restenosis rate and
cardiac events,40-42) the strut thickness of the Jostent and NIR stent is somewhat
similar (90 µm and 100 µm, respectively). All of the results above indicate that
the role of heparin coating remains an open question.35)
Heparins are glycosaminoglycans that, in addition to their anticoagulant
activity, have interactions with growth factors and other glycoproteins. These
interactions may stimulate neointimal hyperplasia when heparin is delivered
locally on stents and stent-grafts. Modifying the structure of heparin to retain its
anticoagulant activity while minimizing these stimulatory effects on the vascular
endothelium is desirable and may be achieved by understanding the relationships
between the structure and functions of the various parts of the heparin mole-
cule.43) The development of the end-point attached heparin-coated stent should be
regarded against the early unfavorable results with uncoated stents in the pre-
IVUS and pre-ticlopidine era. Considering the quite low incidence of early com-
plications of noncoated second generation stents, it may require very large trials
to test the clinical efficacy of the heparin-coating against noncoated devices.
However, even if the 'added value' of the heparin-coating will never be clinically
proven, it has helped to enhance the penetration of stent therapy in interventional
cardiology.44)
In conclusion, the heparin-coated Jostent and the uncoated conventional
NIR stent enable favorable procedural success, (sub)acute thrombosis, and 6-
month restenosis rates and have similar 12-month clinical outcomes.
Limitations of the study: Several limitations can be observed in the current
study. Because this study had a retrospective design, a prospective, randomized
study is mandatory to validate our findings. Another limitation is that computer-
ized quantitative coronary angiography was not available in our laboratory. The
fact the study was performed in a single center is the third limitation. Our timing
for follow-up coronary angiography at 6 months may be too short to evaluate the
restenosis rates of the stents.
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